Anti-CD3/DLL3 Antibody (Tarlatamab)
Catalog No.
F2104
Anti-CD3/DLL3 Antibody (Tarlatamab)
Featured Products
Tarlatamab is a novel bispecific T cell engaging antibody (BiTE) developed by Amgen. It consists of two single-chain variable fragments (scFv), one targeting the CD3 molecule and the other targeting the DLL3 molecule. Tarlatamab activates T cells and kills tumor cells by directing them to tumor cells expressing DLL3, and is mainly used to treat small cell lung cancer (SCLC).
Dry ice
2307488-83-9
-80°C
2 years
Liquid
1 mg/mL
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
AMG 757
100 mM Pro 20 mM Arg pH 5.0.
Human
Unconjugated
Monoclonal
Protein A
IgG1
ELISA, FACS, Kinetics, Functional assay, Animal Model
CD3/DLL3
Please avoid freeze-thaw cycles.